Cytek Biosciences, Inc. officially announced its Enhanced Small Particle (ESP) Detection Option for its Cytek Aurora and Cytek Northern Lights cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for cell analysis, making them the preferred choice among researchers and clinicians. Exosomes are the most commonly studied EV, with a market estimated to increase from $227.5 million in 2023 to $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 20281. Researchers studying exosomes, as well as viruses, small bacteria, and nanoparticles, are moving to flow cytometry because of its high throughput and quantitative detection capabilities.

These capabilities empower to better understand the biogenesis of different types of EVs as well as their biological functions toward using these to both detect and treat disease. The ESP Detection Option on the Cytek Northern Lights and Cytek Aurora systems adds to Cytek's portfolio of small particle solutions, including the Cytek Amnis ImageStream X Mk II imaging flow cytometer, which enables detection of EV production and captures images of EV uptake by cells. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the flow cytometer and imaging products under the Amnis and Guava brands; the Cytek Orion reagent cocktail preparation system, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers.